All In MedTech

Device Trial Radar · NCT07009132

Cholate Clearance in Fontan and Heart Failure

Hepatic Perfusion and Liver Health as Assessed by Dual Cholate Clearance Assay in Fontan-associated Liver Disease (FALD)

Last checked: Nov 19, 2026Latest source record: Sep 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

75

Planned (sponsor's estimate)

Start

Aug 4, 2025

Primary completion

Dec 2026

Study completion Dec 2031

Sponsor

Lead sponsor
HepQuant, LLCNot on our public-company list
Sponsor type
Industry
Collaborators
University of Pennsylvania
First posted
Jun 6, 2025

More device trials from this sponsor

Design

Study type
Observational
FDA-regulated device
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The goal of this study is to use the HepQuant dual cholate clearance assay, which has been shown to measure liver function in people with known chronic liver conditions, to assess severity of Fontan-associated liver disease (FALD). This study aims to understand the role impaired blood flow to the liver plays in liver function in Fontan patients compared to patients with right heart failure and healthy controls. The study will also determine whether cholate clearance is a good measure to use in this population, and whether it will be able to predict clinical outcomes. Participants will undergo a HepQuant dual cholate clearance assay and a cardiac magnetic resonance imaging (MRI) at the beginning of the study, and then data on health status will be collected for 5 years.

Conditions

  • Fontan
  • Right Heart Failure

Interventions

  • Dual cholate clearance assayDevice

    Study participants are administered labeled oral and intravenous cholate, and then two blood samples are taken over 60-minutes. Serum cholate levels are measured by blood draws.

  • MRIRadiation

    Unsedated non contrast cardiac magnetic resonance imaging (MRI)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Hepatic cholate clearanceTime frame: Baseline

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Hospital of the University of Pennsylvania

    Philadelphia, Pennsylvania · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.